Traditional stroke treatments like clot-dissolving tPA and surgical removal of big clots in the brain are good choices as well when the stroke results from SARS-CoV-2 infection, investigators report.
Excessive blood clotting and stroke — even in young, previously healthy people — are among the myriad of effects the virus is having on people across the globe. Another effect is keeping people away from hospitals even when they experience signs of stroke, like sudden and particularly one-sided weakness in the face, arm or leg, say stroke specialists at the Medical College of Georgia and Augusta University Health System.
“What we know about COVID-19 and stroke is people need to be treated urgently and they tend to do really well with tPA and mechanical thrombectomy (clot removal) if they come in within a short time window,” says Dr. David Hess, stroke specialist and MCG dean, who encourages those with signs of stroke for any reason to get to the hospital as soon as possible.
Hess and Dr. Elizabeth Rutkowski, a neurologist whose expertise includes brain infections as well as stroke, are authors of a review paper in the journal Translational Stroke Research highlighting both established and emerging treatment options that may help improve stroke outcomes or reduce stroke risk in these unprecedented times when the extremely infectious SARS-CoV-2 has been added to the traditional risk factors for stroke like high blood pressure and diabetes.
They also have begun a five-year study to assess the overall neurological impact of SARS-CoV-2 infection long term in more than 500 Georgians.
Because signs of the virus’ impact neurologically include not only stroke, but the loss of sense of smell, called anosmia; a reduced sense of taste, called hypogeusia; and brain involvement called encephalopathy that may impact consciousness and cause confusion and headaches, as well as seizures.
In fact, loss of smell can be an early or even lone indicator of SARS-CoV-2 infection. Whether it’s a lasting loss is one of the many things the investigators want to learn. “The hypothesis may be that the people who have anosmia may be more at risk for developing cognitive and other neurological problems,” Hess says.
The brain is a pretty direct target for the virus, which the Centers for Disease Control and Prevention says is mostly spread by human-to-human contact. When an infected individual coughs or sneezes in close proximity, a bystander’s nasal passageway provides a pretty direct route for the virus to first make its way through the olfactory bulb in the front of the brain, which picks up and processes odors detected by cells in the nasal cavity, then to spread throughout the brain. The mouth affords a different route that can take the virus directly to the brain stem, and the neurologists say it’s likely the virus could take both routes in one person.
The direct access to the brain enables a sort of double attack, with a direct hit by the virus to an organ, like the lungs, and to the organ’s control centers in the brain. There are reports, Rutkowski notes, of patients seeming to do better but then they just stop breathing. While she and Hess agree that it’s most often the lung failure that causes death with COVID-19, they suspect it’s both this direct lung invasion and infection of breathing centers in the brain responsible.
While investigators are working in real time to determine what treatments are best for the still emerging array of problems caused by COVID-19, the MCG neurologists say the limited data out there on stroke indicate the standard therapies should work in this scenario as well.
“We think the pathogenesis behind the clots that form during this infection are a little different, but those clots people are describing with COVID-19 are very fresh and tPA seems to be really effective for those,” says Rutkowski. “You see this in people with sepsis and with other viruses,” Hess says of the clotting that can result in stroke and as well as damage to other organs. The neurologists suspect it is this propensity to clot coupled with the virus’ attachment to ACE2 receptors, found throughout the body and considered protective, that leaves patients vulnerable to stroke.
Many viruses, including influenza and shingles, as well as other overwhelming infections such as sepsis, which is often driven by bacteria, result in excessive inflammation which can lead to increased coagulation that causes blood clots, including producing microscopic clots in the tiny air sacs of the lung, that can contribute to adult respiratory distress syndrome — a major cause of severe illness and death in COVID-19 — as well as the dysfunction and failure of other organs.
Patients’ blood will have telltale high levels of D-dimer, a protein fragment produced when a clot is degraded, and their blood clots much faster than usual.
The now familiar spiky virus latches onto the angiotensin converting enzyme 2, or ACE2, an enzyme found on cells — in the lungs, heart, kidneys, intestines and brain as well as the nasal mucosa – which explains its pervasive impact in the body. ACE2 is a part of the renin angiotensin system, which helps regulate blood pressure and is essentially a balance for angiotensin II, a powerful blood vessel constrictor and inflammation promoter. “It probably depletes ACE2 so you get this imbalance, you get too much angiotensin II, which is generally very bad,” Hess says.
Rutkowski notes physicians at Mount Sinai Health System in New York, who have treated hundreds of patients, reporting how dialysis catheters are getting plugged with clots and how clots have even formed on the tip of a catheter during an interventional procedure to remove a clot from the brain.
Confusion is a common problem the neurologists also are seeing in patients with COVID-19, but it’s hard to know in some patients whether that results from the fact that they are so sick and their oxygen levels are low or it’s a direct result of brain infection, Rutkowski says. In others there are clear cases of a brain infection and of virus present in the spinal fluid. As part of their study, which is just getting started, the neurologists will be looking at what happens to cognition and the sense of smell in survivors over time, Rutkowski says, noting that in some pandemics, a viral or bacterial infection actually sets off a neurodegenerative condition that worsens with time. In the wake of the Spanish Flu Pandemic of 1918, for example, physicians were seeing immediate problems like delirium and encephalitis lethargica, which causes troubles like excessive sleepiness and movement problems, and — sometimes years later — a form of Parkinson’s. “We could have the same thing happening here,” Hess says of the current pandemic.
Their new study now underway at MCG and AU Health System likely will be expanded in coming months to MCG campuses statewide, starting with Albany which has one of the highest per capita COVID-19 death rates in the country.
With ongoing concern about COVID-19, those interested in the study can participate remotely or in person. Those enrolled in person will be examined by an MCG neurologist at AU Health System and those enrolled remotely will undergo a telehealth neurological evaluation. Both remote and onsite evaluations will include cognitive testing and a scent identification test where study participants will be asked to identify different smells like chocolate, bubble gum and root beer, queries that will provide more objective measure of changes in the smell sense, Rutkowski says.
They also are taking a more comprehensive look on what type of neurological effects the virus has, and if there are risk factors like preexisting medical problems or gender– males seem preferentially impacted by COVID-19 — that make people more susceptible to those effects, Rutkowski says.
Participants will provide details like medications they are taking, demographics and any COVID-19 related symptoms. Those opting for remote participation will receive similar remote examinations annually for five years. Those who opt for onsite participation will be asked to provide blood samples within a month of diagnosis or soon after a follow-up test shows they are disease free, then again at three and 12 months, then yearly. Blood will be examined for markers of inflammation like cytokines and chemokines and genetic factors like changes in the ACE2 gene that may predispose to neurological problems. Blood also will be examined for the presence and levels off antibodies against the virus and antibodies against sugars coating the virus, both signs of an attack by the immune system.
Blood samples will be studied and stored at the MCG Center for Biotechnology and Genomic Medicine where Dr. Jin-Xiong She, center director, also will be looking at variants in the ACE2 receptor that may make some more vulnerable to neurological problems, as well as antibodies people are making to the natural sugar coating on the virus. She says the antibodies may provide a disease history and help determine whether the severity of symptoms is associated with certain antibodies.
Other collaborators include Dr. John Morgan, director of the Parkinson’s Foundation Center of Excellence and Movement and Memory Disorder Programs in the MCG Department of Neurology, who is conducting cognitive testing; and Dr. Lynnette McCluskey, neurobiologist in the MCG Department of Neuroscience and Regenerative Medicine, who is coordinating smell and taste testing.
Information collected during the study will be shared with the participants’ primary care physician if desired. The investigators hope to add brain imaging to the examination if funding becomes available, Hess says.
In terms of addressing the disease’s impact today, the blood thinner, low molecular weight heparin, used to prevent clots and treat deep vein thrombosis and pulmonary embolism and whose effect is considered to last longer and be more predictable than standard heparin, may be useful in reducing excessive clotting and potentially avoiding a stroke as well as other clot-related organ damage, they say. Rutkowski and Hess note that some physicians are already using it prophylactically and that it’s essentially impossible in the midst of a pandemic to do standard clinical trials to more objectively measure if patients benefit from different therapies.
A more targeted therapy for these patients may be human recombinant soluble ACE2, which has been shown to help restore healthier ACE2 levels and interfere with SARS-CoV-2’s ability to attach to cells, reducing the overall viral load, which decreases disease severity. The clinical grade ACE2 has already undergone early human studies for adult respiratory distress syndrome, the often deadly consequence of this virus, and other significant infections. An interventional study is now enrolling hospitalized adults in Austria, Denmark and Germany.
A clinical trial also is underway in patients with COVID-19 or suspected of having it who have bilateral viral pneumonia, infusing them with the blood vessel dilator angiotensin (1-7), which is significantly depleted in COVID-19 to hopefully improve lung function. Drugs that block the receptor for blood vessel constricting angiotensin II may work from another direction to help restore a healthier balance, the investigators say.
- SIMPLE AND EASY TO USE: The BinaxNOW Self Test from Abbott requires just a shallow nasal swab that you can do yourself; includes easy-to-follow instructions
- SEE RESULTS IN 15 MINUTES: Convenient, fast results anytime, anywhere; no need for a prescription or sending to a lab
- FOR AGES 2 TO ADULT: The self-test is indicated for children as young as 2 years old when administered by an adult, and for all people 15 and older to self-administer
- DESIGNED TO DETECT ACTIVE COVID-19 INFECTION: Includes 2 tests that are indicated for serial testing—simply test yourself twice within 3 days, at least 36 hours apart; designed to detect active infection with or without symptoms
- FOR PERSONAL USE: Does not include a virtual visit for certified digital test results. For proof of negative COVID-19 test, the BinaxNOW COVID-19 Ag Card Home Test may be a better choice.
- 1 AND DONE â THE ONLY 1 AND DONE OTC RAPID HOME COVID ANTIGEN TEST THAT CAN PROVIDE ACCURATE RESULTS IN 15 MINUTES AFTER JUST ONE TEST AND DOES NOT REQUIRE A SECOND TEST AFTER 24-36 HOURS. The Ellume COVID-19 Home Test requires just 1 test and 15 minutes to receive a result. The test kit contents include Analyzer, Nasal Swab with Protective Child Adapter, Dropper, and Processing Fluid.
- FAST, ACCURATE RESULTS â Get reliable results with 1 test in 15 minutes anytime, anywhere, delivered straight to your phone. No prescription required and suitable for adults & children ages 2+ years with or without symptoms. This self-administered COVID test is perfect for individuals, businesses, schools, and events.
- EASY TO USE â The smart solution designed for self-use without the aid of a healthcare professional to deliver fast, highly accurate results in 15 minutes with 1 test once. The patented, user-friendly nasal swab with child adapter is suitable for ages 2+ years.
- SMARTPHONE & BLUETOOTH ENABLED â Download the free Ellume COVID Test App from the Apple or Google Play Store. Follow the information video, perform the easy-to-use test, and get results on your phone in 15 minutes. Mandatory result reporting for COVID mapping happens automatically through a secure, HIPAA compliant cloud connection. Email your result to your employer, family or friends through the app! Required smartphone not included.
- NO PRESCRIPTION REQUIRED - This test has received FDA Emergency Use Authorization for self-testing without the need to ship samples to a lab or for a prescription from your healthcare provider.
- Hardcover Book
- Mercola, Doctor Joseph (Author)
- English (Publication Language)
- 224 Pages - 04/29/2021 (Publication Date) - Chelsea Green Publishing (Publisher)
- Works for symptomatic and asymptomatic individuals
- The QuickVue At-Home OTC COVID-19 Test is intended for the qualitative detection of the nucleocapsid proteins from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two or three days with at least 24 hours and no more than 36 hours between tests
- Ages 2 and up
- Positive results indicate the presence of viral foreign agent, but clinical correlation with past medical history and other diagnostic information is necessary to determine infection status
- How To Use: 1. Swab – Collect a gentle nasal swab sample. 2. Swirl – After adding the swab to the solution tube. 3. Dip – Put the strip into the tube. 4. Read Results – Straightforward and easy to read results
- PACKAGE INCLUDED: 54 "I GOT MY COVID-19 VACCINE" Silicone Wristband, Including 9 Colors, 6 Of Each Color. The Covid Is Terrible, We Should Get Vaccinated!
- GREAT QUALITY: Made Of Soft Silicone, Flexible And Easy To Wear, The Wristband Is Very Lightweight And Can Be Worn Comfortably All Day. The Standard Size Fits Most People.
- IT IS A PROOF: These Wristbands Let Others Know That You Have Been Vaccinated And Will Not Be Affected By Covid-19,And Encourage Others To Participate In Vaccinations As Well.
- SUITABLE FOR ANYONE AND ANY OCCASION: Whether You Are A Man, Woman, Teenager, Medical Professional, You Can Wear This Wristband. It Is A Must-Have Item For Offices, Hospitals, Medical Centers And Clinics.
- 365-DAY NO WORRIED GUARANTEE: We Provide 365-Day Hassle-Free Refund And Exchange Service, Your Satisfaction Is Our Pursuit. If You Have Any Questions, Please Contact Us And We Will Reply Within 24 Hours.
- FDA AUTHORIZED, AT-HOME COVID-19 PCR COLLECTION KIT – Kit for self-collection of a nasal sample, for use by symptomatic and asymptomatic individuals, with shipping to laboratory for detection of SARS-CoV-2—the virus that causes COVID-19. This test is not a "rapid" test, results are available after sending to Amazon's lab for processing. No prescription required.
- CONVENIENT, EASY TO USE – Everything needed for self-collection of nasal sample: Instructions For Use, 1 nasal swab, 1 collection tube with saline, 1 plastic bag with absorbent pad, 1 return box with prepaid return shipping label.
- GOLD STANDARD PCR TEST – Amazon uses what CDC describes as the current “gold standard” for COVID-19 tests, Real-Time RT-Polymerase Chain Reaction, or PCR. While no method is perfect, the CDC identifies PCR as an accurate way to detect infection.
- FAST RESULTS WITH EXPRESS RETURN SHIPPING – Receive easy-to-understand results within 24 hours of your sample arriving at the lab. Collection kit includes prepaid UPS next-day shipping to lab at no additional cost.
- REGISTRATION REQUIREMENT – Prior to shipping the sample to the lab, test registration is required. Registration requires a US mobile phone with text messaging enabled.
- Schwab, Klaus (Author)
- English (Publication Language)
- 280 Pages - 07/09/2020 (Publication Date) - ISBN Agentur Schweiz (Publisher)
- FDA AUTHORIZED HOME TEST FOR SARS-CoV-2 VIRUS DETECTION ON SYMPTOMATIC AND ASYMPTOMATIC INDIVIDUALS – This non-invasive easy to use at-home saliva test for COVID-19 has been FDA authorized for use by both individuals with and without symptoms of COVID-19. The test detects the presence of viral genetic material but will not confirm immunity or detect antibodies. This test is authorized by FDA for emergency use during the COVID emergency.
- SAFE, CONVENIENT, AT-HOME SAMPLE COLLECTION – Kit includes everything needed for sample collection. Only a small amount of saliva sample is needed. Avoid the discomfort of nasal swab and long lines for testing. Registration and sample collection can be done from the comfort of your home or office. Sample collection is unsupervised, so the report may not be valid for all travel purposes.
- FAST RESULTS – Prepaid express return shipping is included with the test. Results are available within 24 to 72 hours of sample receipt at the laboratory. Refund policy: the kit is not returnable once purchased and must be used within 60 days of purchase, refunds will be provided if the physician prescription is not authorized for any reason (such as for having emergency warning symptoms at sample registration) or if results are not provided due to fault of the shipment or testing process.
- ONLINE REGISTRATION AND AUTHORIZATION – Online registration and physician authorization process included with the kit. Samples must be registered into the DxTerity portal and returned to a FedEx collection location on the same day as collection, before the last express pick-up. Samples may not be collected on Sunday in most locations.
- EASY TO UNDERSTAND RESULTS – Fact sheet for patients and the official lab report will be available to you online and may be downloaded to serve as proof of your result. DxTerity developed the test and each sample is processed in our CLIA-Certified (Clinical Laboratory Improvement Amendments) and CAP Accredited (College of American Pathologists) laboratory.
- 2-Pack Vaccination Buttons with Pinbacks - Metal Construction with Mylar Cover for Protection
- Vaccine Awareness Buttons - I got the vaccination
- Please see size chart for more information.
- A great item for the medical community, nursing homes, schools and any public gathering. With everything being cancelled, you can wear this to small gatherings
- FDA AUTHORIZED AT-HOME TEST KIT – The empowerDX COVID-19 Nasal PCR Test has an FDA Emergency Use Authorization (EUA). Our laboratories are CLIA certified and CAP accredited. This test is not for severe symptoms. Approved for ages 3+
- PAIN-FREE – Shallow and pain-free nose swab.
- GETTING RESULTS – Get results within 48 hours of your kit arriving at the lab (overnight return shipping from Mon-Fri).
- SHIPPING INFO – Order today to receive your kit within 2 business days (Mon-Fri only). Free shipping and free overnight return shipping.
- PROCESS – (1) Order your test kit. (2) Perform a shallow and pain-free nasal swab at home. (3) Return your kit with free overnight return shipping the same day you take your sample. (4) Get results within 48 hours of your kit arriving at the lab.
I get commissions for purchases made through links on this website. As an Amazon Associate I earn from qualifying purchases.